The DOI matches its Crossref record.
Treatment of Wilson's Disease With Ammonium Tetrathiomolybdate: I. Initial Therapy in 17 Neurologically Affected Patients
Abstract
OBJECTIVE: To test the efficacy and toxicity of a new drug, ammonium tetrathiomolybdate, in the initial treatment of a relatively large series of patients presenting with neurologic signs and symptoms caused by Wilson's disease. The key aspect of efficacy was to preserve the neurologic function present at the onset of therapy. DESIGN: An open study of 17 patients treated for 8 weeks each. Neurologic function was evaluated by frequent quantitative neurologic and speech examinations. Several copper-related variables were studied to evaluate the effect of the drug on copper, and a large number of biochemical and clinical variables were studied to evaluate potential toxicity. Patients were then followed up at yearly intervals, with follow-up periods of 1 to 5 years reported. SETTING: A university hospital referral setting INTERVENTION: Patients were generally treated for 8 weeks with tetrathiomolybdate, followed by zinc maintenance therapy. MAIN OUTCOME MEASURES: Neurologic function was evaluated by quantitative neurologic and speech examinations. RESULTS: None of the patients suffered a loss of neurologic function. Copper status and potential further toxic effects were generally well controlled quickly. No toxic effects resulted from administration of tetrathiomolybdate. During the ensuing period of follow-up of 1 to 5 years, neurologic recovery in most patients was good to excellent. CONCLUSIONS: Tetrathiomolybdate appears to be an excellent form of initial treatment in patients with Wilson's disease presenting with neurologic signs and symptoms. In contrast to penicillamine therapy, initial treatment with tetrathiomolybdate does not result in further, often irreversible neurologic deterioration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ala, A., Walker, A. P., Ashkan, K., Dooley, J. S., & Schilsky, M. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60196-2 · Cited by 1,446
Diagnosis and treatment of Wilson disease: An update
Roberts, E. A., & Schilsky, M. L. (2008) · Hepatology · doi:10.1002/hep.22261 · Cited by 1,299
Connecting copper and cancer: from transition metal signalling to metalloplasia
Ge, E. J., Bush, A. I., Casini, A., Cobine, P. A., Cross, J. R., DeNicola, G. M., Dou, Q. P., Franz, K. J., Gohil, V. M., Gupta, S., et al. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00417-2 · Cited by 1,298
EASL Clinical Practice Guidelines: Wilson’s disease
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.007 · Cited by 1,243
Barceloux, D. G., & Barceloux, D. (1999) · Journal of Toxicology: Clinical Toxicology · doi:10.1081/clt-100102421 · Cited by 454
Metadata
- Authors
- Brewer, G. J.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 1994-06-01
- Volume
- 51
- Issue
- 6
- Pages
- 545
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2022970217
- Cited by
- 167
- References
- 0
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Wilson's Disease With Ammonium Tetrathiomolybdate: I. Initial Therapy in 17 Neurologically Affected Patients. https://app.cochat.ai/papers/10.1001/archneur.1994.00540180023009
- The paper
- Brewer, G. J. (1994). Treatment of Wilson's Disease With Ammonium Tetrathiomolybdate: I. Initial Therapy in 17 Neurologically Affected Patients. Archives of Neurology. https://doi.org/10.1001/archneur.1994.00540180023009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.